Macrogenics (MGNX) Capital Expenditures Growth (1y) (2013 - 2026)
Macrogenics (MGNX) Capital Expenditures Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 143.40% |
| 10 | Macrogenics | 249.04 Mn | 182.52 Mn | - | -21.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.81% |
| Dec 31, 2025 | -92.42% |
| Sep 30, 2025 | -100.85% |
| Jun 30, 2025 | -55.34% |
| Mar 31, 2025 | 45.87% |
| Dec 31, 2024 | 197.03% |
| Sep 30, 2024 | 511.22% |
| Jun 30, 2024 | -144.02% |
| Mar 31, 2024 | 36.72% |
| Dec 31, 2023 | -262.60% |
| Sep 30, 2023 | -37.94% |
| Jun 30, 2023 | -53.71% |
| Mar 31, 2023 | -87.49% |
| Dec 31, 2022 | -10.48% |
| Sep 30, 2022 | 130.64% |
| Jun 30, 2022 | -51.09% |
| Mar 31, 2022 | 126.04% |
| Dec 31, 2021 | -92.57% |
| Jun 30, 2021 | 264.96% |
| Mar 31, 2021 | -50.04% |